{"id":389318,"date":"2022-12-23T00:00:00","date_gmt":"2022-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0008-2022-biopharma-prostate-cancer-disease-landscape-and-forecast-g7-2022\/"},"modified":"2026-04-26T23:27:35","modified_gmt":"2026-04-26T23:27:35","slug":"dlsfon0008-2022-biopharma-prostate-cancer-disease-landscape-and-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0008-2022-biopharma-prostate-cancer-disease-landscape-and-forecast-g7-2022\/","title":{"rendered":"Prostate Cancer | Disease Landscape and Forecast | G7 | 2022"},"content":{"rendered":"<p>Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment algorithms for nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Some patients with mCRPC are receiving triple combinations of current therapies. The dynamic late-phase pipeline mostly focuses on mCRPC and comprises a plethora of targeted agents (e.g., Janssen \/ GlaxoSmithKline\u2019s Zejula, Pfizer\u2019s Talzenna, Roche\u2019s ipatasertib, AstraZeneca\u2019s capivasertib) and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis\u2019s 177Lu-PSMA-617, Telix\u2019s 77Lu-DOTA-rosopatamab, POINT Biopharma\u2019s 177Lu-PNT2002). These agents will likely contribute to robust market growth over the 2021-2031 forecast period.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?<\/li>\n<li>What are the key drivers and constraints in the prostate cancer therapy market, and how will the major markets evolve over the 10-year forecast period?<\/li>\n<li>What is the current state of treatment for prostate cancer? What are interviewed experts\u2019 insights on these treatment options?<\/li>\n<li>What is the clinical and commercial potential of late-phase pipeline products, and what will their positioning and uptake in the market be?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p>SOLUTION ENHANCEMENT<\/p>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<p>Additionally, Disease Landscape &#038; Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389318","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389318\/revisions"}],"predecessor-version":[{"id":576150,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389318\/revisions\/576150"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}